William Blair Has Negative Estimate for TMDX FY2024 Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Research analysts at William Blair dropped their FY2024 EPS estimates for shares of TransMedics Group in a report issued on Monday, December 2nd. William Blair analyst R. Daniels now expects that the company will post earnings per share of $1.04 for the year, down from their prior estimate of $1.06. The consensus estimate for TransMedics Group’s current full-year earnings is $1.01 per share. William Blair also issued estimates for TransMedics Group’s Q4 2024 earnings at $0.21 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.66 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.55 EPS and FY2026 earnings at $2.44 EPS.

TMDX has been the subject of a number of other research reports. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday. Robert W. Baird reduced their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, JPMorgan Chase & Co. cut their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $72.21 on Wednesday. The firm has a market capitalization of $2.42 billion, a P/E ratio of 76.82 and a beta of 2.06. The company’s fifty day moving average price is $106.99 and its two-hundred day moving average price is $134.90. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a 12 month low of $68.84 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) earnings per share.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,042 shares of company stock valued at $3,563,985 over the last ninety days. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Comerica Bank boosted its holdings in TransMedics Group by 1,072.5% during the 1st quarter. Comerica Bank now owns 14,422 shares of the company’s stock worth $1,066,000 after acquiring an additional 13,192 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of TransMedics Group in the first quarter worth approximately $392,000. Harbor Capital Advisors Inc. increased its position in shares of TransMedics Group by 311.4% in the second quarter. Harbor Capital Advisors Inc. now owns 6,048 shares of the company’s stock worth $911,000 after purchasing an additional 4,578 shares during the last quarter. SG Americas Securities LLC boosted its stake in TransMedics Group by 886.9% in the second quarter. SG Americas Securities LLC now owns 21,189 shares of the company’s stock worth $3,191,000 after buying an additional 19,042 shares in the last quarter. Finally, Capital CS Group LLC purchased a new stake in TransMedics Group in the second quarter worth approximately $659,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.